Listen on the go
CORRECT!
Next question
touchDERMATOLOGY touchDERMATOLOGY

Start Learning

Touch Loading image
touchIN CONVERSATION
Start Learning
Treating moderate-to-severe atopic dermatitis in children and adolescents: Insights from the experts
CE/CME ACCREDITED
touchEXPERT OPINIONS
Start Learning
Navigating treatment choices in high-risk early-stage melanoma
CE/CME ACCREDITED
Luis Ensina, urticaria, drug allergies and angioedema,
JOURNALS
Start Learning
Global impact, Brazilian roots: Prof. Ensina’s journey leading innovation in allergy and immunology
Pyoderma gangrenosum, Benjamin Kaffenberger
JOURNALS
Start Learning
Latest encouraging vilobelimab data in pyoderma gangrenosum
JOURNALS
Start Learning
From Clinic to CNN: Dr. Shari Lipner’s Journey in Advancing Nail Disorders and Mentoring Future Leaders
JOURNALS
Start Learning
FDA approval of nemolizumab gives new treatment option for prurigo nodularis
touchEXPERT BRIEFING
Start Learning
Advances in the treatment of CSU
Sponsored content
Early-onset atopic dermatitis
JOURNALS
Start Learning
Specific cord-blood DNA methylation patterns associated with risk of early-onset atopic dermatitis
androgenic alopecia, ET-02
JOURNALS
Start Learning
ET-02 shows promising 6-fold increase in hair growth in androgenic alopecia
touchMEETING HIGHLIGHTS
Start Learning
Pathophysiological mechanisms and emerging concepts in the management of Type 2 dermatological diseases
Sponsored content

to view Favourites, Keep Notes and Track CME Credits

Favourites
Honouring Prof. Marcus Maurer
View
Specific cord-blood DNA methylation patterns associated with risk of early-onset atopic dermatitis
View
#AAD25: Essential updates in atopic dermatitis and psoriasis
View
Encouraging results for topical 1.5% ruxolitinib cream in milder cases of hidradenitis suppurativa
View
Advances in the treatment of CSU
View
Barzolvolimab shows sustained efficacy over 52 weeks in antihistamine-refractory chronic spontaneous urticaria
View
FDA approval of nemolizumab gives new treatment option for prurigo nodularis
View
Tapinarof 1% in atopic dermatitis: Can patients take a drug holiday and maintain response?
View
ADVENT at ESPD 2024: Type 2 Inflammation in Atopic Dermatitis and the Benefits of Early Intervention
View
Rapid and significant improvements observed with topical ruxolitinb in cutaneous lichen planus
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup